Letter: reduction in projected mortality or need for liver transplantation associated with bezafibrate add‐on in primary biliary cholangitis with incomplete UDCA response
Open Access
- 27 December 2018
- journal article
- letter
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 49 (2) , 236-238
Abstract
Linked ContentThis article is linked to Jones and Hansen, Cheung et al and Cheung et al papers. To view these articles, visit https://doi.org/10.1111/apt.13507, https://doi.org/10.1111/apt.13519 and https://doi.org/10.1111/apt.13465.Keywords
Funding Information
- Arrow Génériques, Lyon, France (RAF 13.022_BEZURSO_P100109_N°VAL 20)
- French Ministry of Health (PHRC 2010 (BEZURSO_P100109))
This publication has 6 references indexed in Scilit:
- A Placebo-Controlled Trial of Bezafibrate in Primary Biliary CholangitisNew England Journal of Medicine, 2018
- Editorial: fenofibrate as second‐line therapy in high risk PBC – more answers or more questions?Alimentary Pharmacology & Therapeutics, 2016
- Editorial: fenofibrate as second‐line therapy in high risk PBC – more answers or more questions? Authors' replyAlimentary Pharmacology & Therapeutics, 2016
- Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid TherapyGastroenterology, 2015
- Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incompleteUDCAresponse may improve outcomesAlimentary Pharmacology & Therapeutics, 2015
- The UK‐PBC risk scores: Derivation and validation of a scoring system for long‐term prediction of end‐stage liver disease in primary biliary cholangitisHepatology, 2015